Vyome Holdings Earnings Call Transcripts
Fiscal Year 2026
-
VT-1953 showed odor, pain, and patient-reported outcome signals in a 15-patient pilot, alongside a safety database exceeding 400 patients. FDA discussions continue on endpoints and a potentially small pivotal program, with a Type C interaction planned.
-
Disciplined execution led to progress in immunoinflammatory and rare disease programs, with VT-1953 advancing toward pivotal trials and a strengthened capital structure. Cash position improved, and a strategic JAK inhibitor in-licensing expands future opportunities.
Fiscal Year 2025
-
Reported $5.7M in cash with runway through 2026, a net loss of $9.2M due to one-time merger charges, and lower than expected cash burn. Interim phase two results for VT1953 were positive, and regulatory engagement for VT1908 is planned for 2026.